 VYGR – Voyager Therapeutics, Inc.
Float Short %
7.51
Margin Of Safety %
Put/Call OI Ratio
0.04
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.96
EPS This/Next Y
0.53
Price
4.1
Target Price
15
Analyst Recom
1.08
Performance Q
-17.51
Relative Volume
1.66
Beta
1.3
Ticker: VYGR
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | VYGR | 4.09 | 0.03 | 0.00 | 6312 |
| 2025-12-29 | VYGR | 4.04 | 0.03 | 0.00 | 6312 |
| 2025-12-30 | VYGR | 3.94 | 0.03 | 0.50 | 6301 |
| 2025-12-31 | VYGR | 3.92 | 0.03 | 0.00 | 6300 |
| 2026-01-02 | VYGR | 4.03 | 0.03 | 0.00 | 6290 |
| 2026-01-05 | VYGR | 4.09 | 0.03 | 0.00 | 6306 |
| 2026-01-06 | VYGR | 4.03 | 0.03 | 0.00 | 6294 |
| 2026-01-07 | VYGR | 4.08 | 0.03 | 0.00 | 6298 |
| 2026-01-08 | VYGR | 4.07 | 0.03 | 0.13 | 6311 |
| 2026-01-09 | VYGR | 4.03 | 0.03 | 0.00 | 6311 |
| 2026-01-12 | VYGR | 3.89 | 0.03 | 4.33 | 6326 |
| 2026-01-13 | VYGR | 4.03 | 0.03 | 0.00 | 6337 |
| 2026-01-14 | VYGR | 4.09 | 0.03 | 0.00 | 6340 |
| 2026-01-15 | VYGR | 3.83 | 0.03 | 0.00 | 6340 |
| 2026-01-16 | VYGR | 3.77 | 0.03 | 0.09 | 6342 |
| 2026-01-20 | VYGR | 3.66 | 0.04 | 0.00 | 3756 |
| 2026-01-21 | VYGR | 3.78 | 0.04 | 0.00 | 3818 |
| 2026-01-22 | VYGR | 4.09 | 0.04 | 0.00 | 3922 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | VYGR | 4.08 | 12.9 | - | -2.09 |
| 2025-12-29 | VYGR | 4.04 | 12.9 | - | -2.09 |
| 2025-12-30 | VYGR | 3.93 | 12.9 | - | -2.09 |
| 2025-12-31 | VYGR | 3.92 | 12.9 | - | -2.09 |
| 2026-01-02 | VYGR | 4.03 | 12.9 | - | -2.09 |
| 2026-01-05 | VYGR | 4.09 | 12.9 | - | -2.09 |
| 2026-01-06 | VYGR | 4.03 | 12.9 | - | -2.09 |
| 2026-01-07 | VYGR | 4.08 | 12.9 | - | -2.09 |
| 2026-01-08 | VYGR | 4.07 | 12.9 | - | -2.09 |
| 2026-01-09 | VYGR | 4.02 | 12.9 | - | -2.09 |
| 2026-01-12 | VYGR | 3.89 | 12.9 | - | -2.09 |
| 2026-01-13 | VYGR | 4.03 | 12.9 | - | -2.09 |
| 2026-01-14 | VYGR | 4.13 | 12.9 | - | -2.09 |
| 2026-01-15 | VYGR | 3.82 | 12.9 | - | -2.09 |
| 2026-01-16 | VYGR | 3.76 | 12.9 | - | -2.09 |
| 2026-01-20 | VYGR | 3.67 | 12.9 | - | -2.09 |
| 2026-01-21 | VYGR | 3.78 | 12.9 | - | -2.09 |
| 2026-01-22 | VYGR | 4.10 | 12.9 | - | -2.09 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | VYGR | -0.27 | -4.15 | 7.42 |
| 2025-12-29 | VYGR | -0.27 | -4.15 | 7.42 |
| 2025-12-30 | VYGR | -0.27 | -4.15 | 7.42 |
| 2025-12-31 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-02 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-05 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-06 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-07 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-08 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-09 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-12 | VYGR | -0.27 | -4.15 | 7.42 |
| 2026-01-13 | VYGR | -0.27 | -4.15 | 7.51 |
| 2026-01-14 | VYGR | -0.27 | -4.15 | 7.51 |
| 2026-01-15 | VYGR | -0.27 | -4.15 | 7.51 |
| 2026-01-16 | VYGR | -0.27 | -4.15 | 7.51 |
| 2026-01-20 | VYGR | -0.27 | -4.18 | 7.51 |
| 2026-01-21 | VYGR | -0.27 | -4.18 | 7.51 |
| 2026-01-22 | VYGR | -0.27 | -4.18 | 7.51 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPSâ
-0.47
Avg. EPS Est. Current Quarter
-0.51
Avg. EPS Est. Next Quarter
-0.49
Insider Transactions
-0.27
Institutional Transactions
-4.18
Beta
1.3
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
9
Fair Value
Quality Score
16
Growth Score
32
Sentiment Score
2
Actual DrawDown %
71.4
Max Drawdown 5-Year %
-80.5
Target Price
15
P/E
Forward P/E
PEG
P/S
7.28
P/B
1.03
P/Free Cash Flow
EPS
-2.17
Average EPS Est. Cur. Yâ
-2.09
EPS Next Y. (Est.)
-1.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-404.85
Relative Volume
1.66
Return on Equity vs Sector %
-84.9
Return on Equity vs Industry %
-69
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
Voyager Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 172
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
stock quote shares  VYGR – Voyager Therapeutics, Inc. Stock Price stock today
news today  VYGR – Voyager Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch  VYGR – Voyager Therapeutics, Inc. yahoo finance google finance
stock history  VYGR – Voyager Therapeutics, Inc. invest stock market
stock prices VYGR premarket after hours
ticker VYGR fair value insiders trading